Standout Papers

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer 2011 2026 2016 2021 5.4k
  1. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer (2011)
    Thierry Conroy, Françoise Desseigne et al. New England Journal of Medicine
  2. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib (2014)
    Andrew X. Zhu, Masatoshi Kudo et al. JAMA
  3. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma (2023)
    Shukui Qin, Masatoshi Kudo et al. JAMA Oncology

Immediate Impact

3 by Nobel laureates 13 from Science/Nature 92 standout
Sub-graph 1 of 18

Citing Papers

Pancreatic cancer
2025 Standout
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
2024 Standout
51 intermediate papers

Works of Eric Assénat being referenced

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
2023 Standout
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
2017
and 5 more

Author Peers

Author Last Decade Papers Cites
Eric Assénat 6994 1594 2391 2619 171 9.9k
Rosine Guimbaud 7517 882 2452 2328 177 9.3k
Jean‐Luc Van Laethem 7704 1123 3103 2154 275 10.1k
Edwin P. Hui 3857 936 1714 2164 170 8.7k
Shoji Nakamori 4355 1589 1845 2005 274 9.9k
Robert R. McWilliams 5770 729 1859 1848 204 8.1k
Brigette Ma 4705 1182 2288 2398 243 9.9k
Daniel H. Palmer 5174 3231 2923 1848 211 11.3k
Antoine Adenis 10134 1229 5225 2882 212 13.8k
Jean‐Baptiste Bachet 11132 875 4076 3989 210 13.2k
Antoine Hollebecque 6269 1059 2951 1471 308 10.8k

All Works

Loading papers...

Rankless by CCL
2026